PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD
LA JOLLA, Calif. , Feb. 13, 2020 /PRNewswire/ --  Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it initiated dosing of the second cohort of its Phase 1 multiple
View HTML
Toggle Summary Regulus Therapeutics Announces FDA Removal of Partial Clinical Hold for Multiple Ascending Dose Study of RGLS4326
Regulus Plans to Re-Initiate Clinical Studies in Q1 2020 Milestone for Second Tranche of Private Financing of Approximately $25.1 Million Achieved LA JOLLA, Calif. , Dec. 16, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and
View HTML
Toggle Summary Regulus Therapeutics to Present at the Stifel Healthcare Conference
LA JOLLA, Calif. , Nov. 18, 2019 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Therapeutics Reports Third Quarter 2019 Financial Results and Recent Updates
Receipt of Final Reports from the Chronic Toxicity Studies for Submission of Complete Response to Reinitiate the Multiple Ascending Dose Clinical Study for RGLS4326 Appointment of Cris Calsada as New Chief Financial Officer LA JOLLA, Calif. , Nov. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc.
View HTML
Toggle Summary Regulus Therapeutics Presents Preclinical Data Identifying RGLS4326 as a Potential Disease-Modifying Treatment for Autosomal Dominant Polycystic Kidney Disease at OTS Annual Meeting
LA JOLLA, Calif. , Oct. 16, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS) , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today announced that it presented preclinical data that identifies RGLS4326, a
View HTML
Toggle Summary Regulus Therapeutics Announces Publication in Nature Communications Identifying RGLS4326 as a Potential Promising Treatment for ADPKD
LA JOLLA, Calif. , Sept. 12, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that  Nature Communications  has published an article entitled, "Discovery
View HTML
Toggle Summary Regulus Therapeutics to Present at the H.C. Wainwright Global Investment Conference
LA JOLLA, Calif. , Sept. 3, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Therapeutics to Present at the Wells Fargo Healthcare Conference
LA JOLLA, Calif. , Aug. 29, 2019 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that Jay Hagan , President and Chief Executive Officer of Regulus, will
View HTML
Toggle Summary Regulus Therapeutics Reports Second Quarter 2019 Financial Results and Recent Updates
Closing of First Tranche of $41.8 Million Private Placement of Equity Term Loan Restructured Providing Up to Two Years of Interest Only and Extended Maturity Date to May 2022 Data Requirements Defined to Reinitiate Multiple Ascending Dose and Chronic Dose Studies with RGLS4326 Appointment of Cris
View HTML
Toggle Summary Regulus Therapeutics Appoints Cris Calsada as Chief Financial Officer
LA JOLLA, Calif. , July 30, 2019 /PRNewswire/ -- Regulus Therapeutics Inc .  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Cris Calsada as its new Chief Financial Officer effective
View HTML